Allergen immunotherapy is effective in patients with IgE-dependent allergic rhinitis and
asthma. When immunotherapy is given continuously for 3 years, there is persistent clinical …

Substantial progress in understanding mechanisms of immune regulation in allergy, asthma,
autoimmune diseases, tumors, organ transplantation and chronic infections has led to a …

Since the discovery of immunoglobulin E (IgE) as a mediator of allergic diseases in 1967,
our knowledge about the immunological mechanisms of IgE‐mediated allergies has …

The availability of allergen molecules ('components') from several protein families has
advanced our understanding of immunoglobulin E (IgE)‐mediated responses and enabled …

This article continues the comprehensive international consensus (ICON) statement on
allergen immunotherapy (AIT). The initial article also recently appeared in the Journal. The …

Acute allergic symptoms are caused by allergen-induced crosslinking of allergen-specific
immunoglobulin E (IgE) bound to Fc-epsilon receptors on effector cells. Desensitization with …

Allergen‐specific immunotherapy (AIT) is an allergen‐specific form of treatment for patients
suffering from immunoglobulin E (IgE)‐associated allergy; the most common and important …

In the past, the development of more effective, safe, convenient, broadly applicable, and
easy to manufacture vaccines for allergen-specific immunotherapy (AIT) has been limited by …

Today, in vivo allergy diagnosis and allergen-specific immunotherapy (AIT) are still based
on allergen extracts obtained from natural allergen sources. Several studies analyzing the …

Immunoglobulin E (IgE)-associated allergy is the most common immune disorder. More than
30% of the population suffer from symptoms of allergy which are often severe, disabling, and …